MICROBA LIFE SCIENCES LIMITED (MAP)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MAP

MAP - MICROBA LIFE SCIENCES LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.07
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.09

15 Aug
2025

0.000

OPEN

$0.09

0.000

HIGH

$0.09

861,131

LOW

$0.08

TARGET
$0.235 161.1% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
MAP: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 4.9 - 2.7 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 24/06 - (franking Ex-Di

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 20202021202220232024
EPS Basic xxxxxxxxxxxx-4.9
DPS All xxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxx12.1 M
Book Value Per Share xxxxxxxxxxxx9.2
Net Operating Cash Flow xxxxxxxxxxxx-15.6 M
Net Profit Margin xxxxxxxxxxxx-164.92 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 20202021202220232024
Return on Capital Employed xxxxxxxxxxxx-49.98 %
Return on Invested Capital xxxxxxxxxxxx-49.60 %
Return on Assets xxxxxxxxxxxx-37.98 %
Return on Equity xxxxxxxxxxxx-49.98 %
Return on Total Capital xxxxxxxxxxxx-64.94 %
Free Cash Flow ex dividends xxxxxxxxxxxx-17.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 20202021202220232024
Short-Term Debt xxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxx8 M
Cash & Equivalents - Generic xxxxxxxxxxxx21 M
Price To Book Value xxxxxxxxxxxx1.74

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 20202021202220232024
Capex xxxxxxxxxxxx4.4 M
Capex % of Sales xxxxxxxxxxxx36.22 %
Cost of Goods Sold xxxxxxxxxxxx21 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxx18 M
Research & Development xxxxxxxxxxxx11 M
Investments - Total xxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

23/07/2025

1

Speculative Buy

$0.31

244.44%

Morgans describes Microba Life Sciences' June quarter as a strong finish to FY25, with results marginally ahead of expectations and in line with guidance.

Growth in MetaXplore testing was a key driver, with Australian sales up 88% year-on-year and early traction continuing in the UK, where test sales rose 74% quarter-on-quarter. MetaPanel adoption also improved, with test volumes up 85%.

The company reported quarterly revenue of $4.2m and an operating cash outflow of $5.6m, closing with $11.8m in cash and further funding secured via a placement and expected R&D rebate.

FY26 guidance includes breakeven on a regional basis in Australia and the UK, and more than 24,000 core test volumes, compared to an annualised run rate of 13,800, explains Morgans.

The broker lowers its target to 31c from 32c and maintains a Speculative Buy rating.

FORECAST
Morgans forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -2.60 cents.
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -2.10 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

16/08/2025

1

Resume at Buy

$0.19

111.11%

Following a period of research restriction, Canaccord Genuity resumed coverage of Microba Life Sciences with a Buy rating.

The broker revised forecasts to account for recent capital raise and 4Q25 update. FY25 revenue grew 30% y/y on strong 4Q rebound following 3Q mix shift, leading to record 4Q test sales of 3,451, up 88% y/y.

The company raised $14.5m via $12.5m placement and $2m share purchase plan, with Sonic Healthcare ((SHL)) committing up to $8.3m.

Upside risks include faster adoption in AU/UK, especially MetaPanel uptake by high-volume clinics and MAP-315 monetisation, with a potential deal not included in forecasts.

Target trimmed to 19c from 26c.

FORECAST
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -3.00 cents.
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -2.00 cents.
Access Extra Coverage Research History >

MAP STOCK CHART

FNArena News on MAP

1
Australian Broker Call *Extra* Edition – Aug 18, 2025 (Extra)

11:15 AM - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Aug 18, 2025

10:30 AM - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Aug 12, 2025

Aug 12 2025 - Daily Market Reports
4
In Case You Missed It – BC Extra Upgrades & Downgrades – 30-05-25

May 30 2025 - Weekly Reports
5
Australian Broker Call *Extra* Edition – May 29, 2025

May 29 2025 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Renewed Momentum For CSL Shares

Jul 22 2025 - Technicals
2
Treasure Chest: CSL Not A One-Trick Pony

Jul 14 2025 - Treasure Chest
3
The Enigma Surrounding Clinuvel

Jul 03 2025 - Small Caps
4
Rudi’s View: CSL & NextDC

May 08 2025 - Rudi's View
5
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia
6
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
7
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
8
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
9
CSL Shares Breaking Free

Jul 23 2024 - Technicals
10
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps